Specialized brain scans may accurately predict whether a psychotic patient will go on to develop treatment-resistant schizophrenia, Dutch researchers report. The scan -- called a ...

Newron announces US initiation of its ENIGMA-TRS 2 Phase III global study of evenamide for patients with treatment-resistant ...

Please provide your email address to receive an email when new articles are posted on . Evenamide was associated with clinically significant improvements in treatment-resistant schizophrenia at 6 ...

The Psychiatry and Mental Health research group at the Germans Trias i Pujol Research Institute (IGTP), together with the ETEP (Study and Treatment of Psychotic Episodes) group at Hospital del Mar, ...

Medication management of patients on clozapine is impacted when individuals start or stop cigarette smoking. A reduction in cigarette smoking or smoking cessation increases clozapine plasma ...

MILAN--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the ...

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) just unveiled an announcement. Newron Pharmaceuticals has announced the US launch of its global Phase ...

Lucid Capital analyst Elemer Piros initiated coverage of Newron Pharma (NWPHF) with a Buy rating and CHF 73 price target The ...

I remember the first time I heard the time "treatment resistant." It was from a friend as they shared with me their mental health story. As this conversation took place some years before my schooling ...

ENIGMA-TRS 1 is an international, one-year, double-blind, placebo-controlled Phase III study in at least 600 patients; enrollment to start imminently; 12-week study results expected in Q4 2026 ...